In contrast, agonistic CD40 mAb therapy did not enhance IDO1 expression in CD45+ leukocytes, and the relative level of expression was considerably lower in leukocytes than what was observed in tumor endothelial cells after agonistic CD40 mAb therapy (Supplemental Fig S4C). Here, PTPRC is linked to neoplasm.